Skip to main content

Adult laryngeal Embryonal Rhabdomyosarcoma: a case report and literature review



Laryngeal rhabdomyosarcomas (RMSs) mainly occurred in children, while were extremely rare in adults. Consequently, less information was available to guide clinicians to manage adult RMSs in larynx.

Case presentation

A 42-year-old man presented with a 2-year history of gradually worsening hoarseness. Then, he underwent a surgery with suspension laryngoscope with initially being diagnosed as vocal cord cyst. Unexpectedly, the lesion was proved to be embryonal rhabdomyosarcoma (ERMS), pathologically. Next, he underwent chemoradiotherapy, while the tumor relapsed 18 months after the last treatment. Subsequently, a vertical hemilaryngectomy and a right selective neck dissection was performed, and the chemotherapy according to the anticancer drug sensitivity in vitro was arranged. Until the last check-up 18 months after chemotherapy, the patient did not display clinical or radiological signs of local recurrence and metastases.


Misdiagnosis and missed diagnosis of laryngeal RMSs might appear when tumors presented as smooth protuberance. We reported the first case of laryngeal RMSs in an adult with the multidisciplinary strategy based on the chemosensitivity assay in vitro. Furthermore, a systematic review of the literature was also discussed, highlighting the initial diagnostic pitfalls and subsequent management problems that may occur with this uncommon tumor.

Peer Review reports


Primary laryngeal sarcomas constitute less than 1% of all malignant laryngeal tumors [1], and more than 50% of these tumors are fibrosarcomas, followed by osteosarcomas, chondrosarcomas, liposarcomas, leiomyosarcomas, and rhabdomyosarcomas (RMSs) [2]. RMSs usually involve in skeletal muscle, and thus can be localized in almost any site [3]. Around 40% cases originate in the head and neck region, while RMSs arising in the larynx are extremely rare [4, 5]. Laryngeal RMSs, arising from undifferentiated mesodermal tissue, mainly occurred in children. To date, only 22 cases of laryngeal RMSs in adults have been reported (Table 1). As a result, less information was available to guide clinicians to manage adult RMSs in larynx. We reported the first case of laryngeal RMSs in an adult with the multidisciplinary strategy based on the chemosensitivity assay in vitro.

Table 1 Reported cases of laryngeal rhabdomyosarcoma in adults

Case presentation

A 42-year-old man presented with a 2-year history of gradually worsening hoarseness without pain, dyspnoea or dysphagia. He had no history of alcohol or tobacco use. Flexible laryngoscopy in January 2016 showed a reddish, smooth and submucosal mass with protrusion medially in the anterior third of the right vocal cord, and glottic closure was incomplete posteriorly with normal mobility (Fig. 1a). Given the well-circumscribed and relatively benign appearance, the lesion was initially suspected to be vocal cord cyst. Then the patient was planned to undergo surgery with suspension laryngoscope. Unexpectedly, the tumor was found to be fleshy, crisp and easily bleeding without invading anterior commissure. Therefore, a frozen pathology was sent during the operation, and indicated malignancy (Fig. 1b). However, the definitive pathologic diagnosis could not be made in the operation. Besides, the scope of the lesion and the lymph nodes of the neck was not defined, due for the lack of preoperative computed tomography (CT) / the magnetic resonance imaging (MRI). Therefore, the combined therapy regimen (surgery, chemotherapy or radiotherapy) cannot be formulated. Ultimately, we performed a cordectomy with the visible lesion for the patient. The final diagnose was embryonal rhabdomyosarcoma (ERMS) with immunohistochemical staining positivity for myogenin, smooth muscle actin (EMA), desmin and myoD1 (Fig. 1c). In order to develop further therapeutic regime, the MRI was performed, and showed an asymmetric swelling of the right vocal cord with no lymphadenopathy being detected in the neck (Fig. 1d). After evaluation of the tumor size, grade, and lymph node involvement, we recommended extended resection or combined chemoradiotherapy, and the patient chose the latter. He underwent three cycles of induction chemotherapy with TDF regimen (paclitaxel, cisplatin and fluorouracil) at 3-week intervals. In addition, he received a mean radiation dose of 70 Gray (Gy) to the laryngeal area. After treatment, the larynx presented with smooth appearance and good mobility of vocal cord.

Fig. 1

Imaging of initial treatment of this new reported case. a, The lesion (labeled with asterisk) was covered with normal mucosa without any ulcerations by flexible laryngoscopy. b, The majority of the tumor consisted of spindle-shaped cells with nucleus located centrally and eosinophilic-abundant cytoplasm (HE staining × 20). c, Immunohistochemistry was positive for myogenin, EMA, desmin and myoD1 (Original magnification for all slides is ×20.) d, MRI imaging showed the right vocal cord swelling several days after the first operation. e, On evaluations with MRI 1 year after the first multi-treatment, there was complete regression of the disease. Scale: 50um

The patient was followed up as scheduled with no recurrence (Fig. 1e). One year later, he lost follow-up until the presence of dyspnea 18 months after the last treatment. Flexible laryngoscopy (Fig. 2a), MRI imaging (Fig. 2b) and CT imaging (Fig. 2c) showed a submucosal mass of the right vocal cord. Intraoperative findings showed that the tan mass originated from the right vocal cord, invaded the anterior commissure and bulged into right perilaryngeal soft tissues without involving the laryngeal cartilage. Therefore, a vertical hemilaryngectomy and a right selective neck dissection was performed. No tumor cells were detected along the surgical margin and in the lymph nodes of the neck. Histological examination of the whole specimen postoperatively confirmed the diagnosis of ERMS. The tumor was clinically staged as T3N0M0 (stage III) glottic ERMS. Then the experiment of anticancer drug sensitivity of this tumor to eight chemotherapeutic regimens was determined in vitro, revealing that DCF regimen (docetaxel, cisplatin and fluorouracil) was the most efficient (Fig. 2d). Finally, the patient underwent DCF regimen at 3-week intervals without radiotherapy. Until the last check-up 18 months after chemotherapy, the patient did not display clinical or radiological signs of local recurrence and metastases (Fig. 3).

Fig. 2

Imaging of second treatment of this new reported case. a, Flexible laryngoscopy revealed that a submucosal mass bulged the right true vocal cord medially and pressed the left true vocal fold with no restrictive mobility of bilateral vocal cords. b, MRI imaging showed that the lesion caused a partial obstruction at the level of the glottis with the size of 1.6 × 1.2 × 1.7 cm. c, No evidence of thyroid cartilage invasion was detected in the CT imaging. d, Anticancer drug sensitivity of this tumor to eight chemotherapeutic regimens was conducted, and revealed that docetaxel, cisplatin and fluorouracil was the most efficient

Fig. 3

The timeline of medical record of the new reported case

Discussion and conclusions

The first case of laryngeal RMS was reported by Glick in 1944 [22]. Subsequently, most of these reported cases have occurred in children and more than 70% of RMSs were diagnosed younger than 10 years. In contrast, laryngeal RMSs occurred very infrequently in adults [13], and were more commonly found in males than females. Reviewing the 22 well-documented cases in the English-language literature, 18 cases were males (81.8%) versus 4 cases of female (18.2%). Meanwhile, laryngeal RMSs in adults were predominantly reported in the glottic and supraglottic region (Table 2). The clinical features of the case in this study were similar with previous cases.

Table 2 Summary of reported cases of laryngeal rhabdomyosarcoma in adults

The clinical features and macroscopic appearances do not differ substantially from the other laryngeal tumors, therefore, the initial diagnosis of laryngeal RMS in adults may be difficult [13]. The most common symptoms and signs, including hoarseness, dyspnea, stridor, dysphagia and polypoid appearance, provided limited diagnostic information [11]. To review the literature, RMSs had been misdiagnosed as hemangioma [23] and laryngopharyngeal reflux [7]. Our case was initially diagnosed as the vocal cord cyst, due for the cystic appearance, and the overlying mucosa was smooth. Therefore, stroboscopy or narrow-band imaging was not performed. This was the main reason of misdiagnosis, which reminded us that for vocal cord tumor, diagnosis should be combined with stroboscopy, narrow band imaging and other comprehensive evaluations, instead of clinical experience or the appearance. CT was often preferred with the information of whether laryngeal cartilage or bone erosion [10]. MRI enabled us to perform a noninvasive assessment of tumor size, localization, nerve or vascular invasion. While CT/ MRI proved to be incapable of distinguishing RMSs from other laryngeal malignant tumors.

Therefore, the definite diagnosis is based on optical microscope and immunohistochemistry [2]. Positivity for vimentin indicates the mesenchymal origin, and the staining for actin, desmin, myogenin and myoglobin suggests muscular differentiation. The histological classification of RMS is controversial. Most authors accepted the system proposed by Horn and Enterline [24] that there were three principal histological varieties of RMS: embryonal, alveolar, pleomorphic according to their degree of cellular differentiation and maturity; both spindle cell RMSs and botryoid RMSs were considered to be subtypes of embryonal RMSs [25]. The embryonal subtype is the most frequent, accounting for 70–75% of all RMSs, followed by the alveolar (20–25%) and pleomorphic differentiation (5%) [2]. To date, there were 22 cases of laryngeal RMS in adults, including 13 (59.09%) pleomorphic RMS, 7 (31.82%) embryonal RMS and 2 (9.09%) alveolar RMS (Table 2). The case described here was an adult with the type of ERMS, which did not accord with this general pattern concerning the preponderance of age and pathological type. ERMS of the larynx must be differentiated from other common histological types in that it differs significantly with respect to its management [4].

The management of RMSs has evolved from radical surgery to less morbid regimen, which is now typically limited to organ-sparing procedures supplemented with chemoradiotherapy. This paradigm shift can be attributed to the multimodality protocols initiated by the Intergroup Rhabdomyosarcoma Study Group (IRSG) over several decades [9, 26, 27]. Since RMSs are rare in the adult population, there is no standard adult-specific chemoradiation protocols, so far, most of the chemoradiation protocols refer to pediatric series. The treatment responses of radiotherapy were variable and difficult to interpret, as radiotherapy often followed radical excision of the tumor. Markedly, ERMS of the larynx appears to be highly responsive to chemotherapy. However, further studies are required in order to improve the comprehending of their biological behaviors and to draft the optimum therapeutic approach. Nowadays, the experiment of anticancer drug sensitivity in vitro is the evidence in the chemotherapy and has become a highlight for the realization of individual tumor treatment [28, 29]. In our case, the tumor relapsed via microlaryngoscopic surgery combined with initial chemoradiotherapy. Therefore, we adopted more aggressive surgical intervention, and adjusted chemotherapy regimen according to the chemosensitivity assay in vitro (Fig. 2d). Finally, the patient has been remaining disease-free until now. Totally, the optimal therapy for laryngeal RMSs in adults is a multimodal approach comprising surgery followed by chemo- (in line with the anticancer drug sensitivity) and/or radiotherapy.

Although the survival rate of RMSs has been improved from 25% in 1970 to approximately 75% today, local tumor recurrence and metastasis remained challenging. Some authors noted that micro-metastasis is presumed leading to the high rate of failure with surgery alone [30]. Prognostic indicators, including age, tumor location, histologic subtype and response to treatment, have been identified. Hawkins [31] reported that patients with age < 20 years and those with a tumor size < 5 cm had a better prognosis. Multi-institutional pediatric trials have showed a 70% cure rate in children without metastatic disease, whereas adults had a poor prognosis. This may be implicated in the discrepancy of histologic variation that unfavorable subtypes (such as the pleomorphic RMSs) are more common in adults [32]. The embryonal subtype has a better overall prognosis associated with earlier age of onset, and the alveolar subtype, which accounts for the least, tends to carry the worst prognosis. Notably, laryngeal RMSs are supposedly less aggressive than RMSs elsewhere, presumably due to the cartilaginous borders of the larynx restricting local tumor spread [13]. Reviewing the 22 cases in the English-language literature, there were 21 cases receiving treatment (surgery, chemotherapy, radiotherapy or combination therapy) with 2 cases being lost to follow-up. Among these 19 cases, 17 cases were alive and disease-free at the ending of follow-up; 2 patients died of extensive distant metastases, and the pathological type was alveolar RMS and pleomorphic, respectively. The present case here did neither show systemic metastasis and is alive with disease-free after more than 18 months of follow up. However, late relapses warrant long-term follow up.

This was an unusual occurrence of an ERMS in the larynx of a middle-aged man who was a non-smoker. Misdiagnosis and missed diagnosis of laryngeal RMSs might appear when tumors presented as smooth protuberance. Therefore, it is important for otolaryngologists to remain vigilant and to suspect, confirm, and localize these tumors. Presently, multidisciplinary treatment based on the anticancer drug sensitivity remains the mainstay of the management, and offers best results to the patients. This is ideal, but not represent the reality around the word.

Availability of data and materials

All data generated or analysed during this study are included in this published article.





Embryonal rhabdomyosarcoma


Smooth muscle actin


Magnetic resonance imaging


Computed tomography












Hematoxylin-eosin staining


  1. 1.

    Mungan S, Arslan S, Küçüktülü E, Ersöz Ş, Çobanoğlu B. Pleomorphic Rhabdomyosarcoma arising from true vocal fold of larynx: report of a rare case and literature review. Case Rep Otolaryngol. 2016;2016:8135967.

    PubMed  PubMed Central  Google Scholar 

  2. 2.

    Schrock A, Jakob M, Zhou H, Bootz F. Laryngeal pleomorphic rhabdomyosarcoma. Auris Nasus Larynx. 2007;34(4):553–6.

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Pittore B, Fancello G, Cossu Rocca P, Ledda GP, Tore G. Rhabdomyosarcoma: a rare laryngeal neoplastic entity. Acta Otorhinolaryngol Ital. 2010;30(1):52–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Kukwa W, Wojtowicz P, Jagielska B, Sobczyk G, Kukwa A, Czarnecka AM. Laryngeal embryonal rhabdomyosarcoma in an adult - a case presentation in the eyes of geneticists and clinicians. BMC Cancer. 2011;11:166.

    PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Diehn KW, Hyams VJ, Harris AE. Rhabdomyosarcoma of the larynx: a case report and review of the literature. Laryngoscope. 1984;94(2 Pt 1):201–5.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Chiramel GK, Chacko BR, Thomas R, Jebakumar D. A rare and unusual occurrence of rhabdomyosarcoma arising from the larynx. Indian J Cancer. 2015;52(1):125–6.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Li Y, Fu Z, Chen W, Yang L, Zhu W. Embryonal Rhabdomyosarcoma of the Adult's vocal cord: a case report. Iran Red Crescent Med J. 2015;17(8):e28876.

    PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Russell JO, Revenaugh PC, Budd GT, Greskovich J, Scharpf J. Failed organ preservation strategy for adult laryngeal embryonal rhabdomyosarcoma. Am J Otolaryngol. 2015;36(2):277–9.

    PubMed  Article  Google Scholar 

  9. 9.

    Leventhal DD, Spiegel J, Keane W. Laryngeal alveolar rhabdomyosarcoma involving the true vocal fold in an adult: case report. Ear Nose Throat J. 2010;89(12):E8.

    PubMed  Article  Google Scholar 

  10. 10.

    Papacharalampous GX, Manolopoulos L, Korres S, Dicoglou C, Bibas A. Adult laryngeal rhabdomyosarcoma: is aggressive treatment justified in all cases? A case report and review of the literature. J Laryngol Otol. 2009;123(11):e21.

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Dikbas O, Altundag K, Abali H, Turker A, Engin H, Sungur A, et al. Embryonal rhabdomyosarcoma of the larynx. Otolaryngol Head Neck Surg. 2005;133(1):160–2.

    PubMed  Article  Google Scholar 

  12. 12.

    Libera DD, Falconieri G, Zanella M. Embryonal "Botryoid" rhabdomyosarcoma of the larynx: a clinicopathologic and immunohistochemical study of two cases. Ann Diagn Pathol. 1999;3(6):341–9.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Ruske DR, Glassford N, Costello S, Stewart IA. Laryngeal rhabdomyosarcoma in adults. J Laryngol Otol. 1998;112(7):670–2.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Akyol MU, Sözeri B, Küçükali T, Oğretmenoğlu O. Laryngeal pleomorphic rhabdomyosarcoma. Eur Arch Otorhinolaryngol. 1998;255(6):307–10.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Da Mosto MC, Marchiori C, Rinaldo A, Ferlito A. Laryngeal pleomorphic rhabdomyosarcoma. A critical review of the literature. Ann Otol Rhinol Laryngol. 1996;105(4):289–94.

    PubMed  Article  Google Scholar 

  16. 16.

    Balázs M, Egerszegi P. Laryngeal botryoid rhabdomyosarcoma in an adult. Report of a case with electron microscopic study. Pathol Res Pract. 1989;184(6):643–9 discussion 649-51.

    PubMed  Article  Google Scholar 

  17. 17.

    Haerr RW, Turalba CI, el-Mahdi AM, Brown KL. Alveolar rhabdomyosarcoma of the larynx: case report and literature review. Laryngoscope. 1987;97(3 Pt 1):339–44.

    CAS  PubMed  Google Scholar 

  18. 18.

    Srinivasan U, Talvalkar GV. True carcinosarcoma of the larynx: a case report. J Laryngol Otol. 1979;93(10):1031–5.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Winter LK, Lorentzen M. Rhabdomyosarcoma of the larynx. Report of two cases and a review of the literature. J Laryngol Otol. 1978;92(5):417–24.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Frugoni (Verona) P, Ferlito (Padua) A. Pleomorphic rhabdomyosarcoma of the larynx. A case report and review of the literature. J Laryngol Otol. 1976;90(7):687–98.

    CAS  Article  Google Scholar 

  21. 21.

    Hall-Jones J. Rhabdomyosarcoma of the larynx. J Laryngol Otol. 1975;89(9):969–76.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Rodriguez LA, Ziskind J. Rhabdomyosarcoma of larynx. Laryngoscope. 1970;80(11):1733–9.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Cobanoglu B, Simsek M, Senol S. Rhabdomyosarcoma of the upper lip in an adult patient. Case Rep Med. 2015;2015:508051.

    PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Newton WA Jr, Gehan EA, Webber BL, Marsden HB, van Unnik AJ, Hamoudi AB, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification--an intergroup Rhabdomyosarcoma study. Cancer. 1995;76(6):1073–85.

    PubMed  Article  Google Scholar 

  25. 25.

    Knipe TA, Chandra RK, Bugg MF. Sclerosing rhabdomyosarcoma: a rare variant with predilection for the head and neck. Laryngoscope. 2005;115(1):48–50.

    PubMed  Article  Google Scholar 

  26. 26.

    Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001;19(12):3091–102.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The third intergroup Rhabdomyosarcoma study. J Clin Oncol. 1995;13(3):610–30.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Unger FT, Klasen HA, Tchartchian G, de Wilde RL, Witte I. DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells. BMC Cancer. 2009;9:359.

    PubMed  PubMed Central  Article  Google Scholar 

  29. 29.

    Isogai A, Nagaya M, Matsuoka H, Watanabe T, Tsukikawa S, Kubota S. An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer. Surgery. 2007;142(5):741–8.

    PubMed  Article  Google Scholar 

  30. 30.

    Wagemans J, Beuselinck B, Nuyts S, Sciot R, Delaere P, Vander Poorten V, et al. A case series of embryonal rhabdomyosarcoma of the head and neck in adults. Acta Clin Belg. 2010;65(6):404–10.

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Hawkins WG, Hoos A, Antonescu CR, Urist MJ, Leung DH, Gold JS, et al. Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer. 2001;91(4):794–803.

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol. 2009;27(20):3391–7.

    PubMed  Article  Google Scholar 

Download references




This work was supported by the Major Subject of the Science and Technology Department of Sichuan Province (No. 2017SZ0015) (to Hui Yang). Dr. Hui Yang studied the concept and designed the report. In this study, laboratory analyses and cover publication costs were supported by the funding.

Author information




JH and DL drafted the manuscript. JZ and HY studied the concept and designed the report. JR, SL, and JL diagnosed and treated the patients. QW, JZ, and WG followed up the patients. All authors have read and approved the manuscript.

Corresponding author

Correspondence to Jian Zou.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hu, J., Lu, D., Ren, J. et al. Adult laryngeal Embryonal Rhabdomyosarcoma: a case report and literature review. BMC Surg 20, 173 (2020).

Download citation


  • Rhabdomyosarcoma
  • Laryngeal rhabdomyosarcomas
  • Multidiscipline
  • Anticancer drug sensitivity